ClinicalTrials.gov
ClinicalTrials.gov Menu

Drug Interaction Study of MGL-3196 With Atorvastatin

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02749578
Recruitment Status : Completed
First Posted : April 25, 2016
Last Update Posted : August 30, 2016
Sponsor:
Collaborator:
Celerion
Information provided by (Responsible Party):
Madrigal Pharmaceuticals, Inc.

Brief Summary:
The purpose of this study is to determine whether MGL-3196 alters the pharmacokinetics of atorvastatin in healthy male subjects and female subjects not of child-bearing potential.

Condition or disease Intervention/treatment Phase
Healthy Drug: Atorvastatin Drug: MGL-3196 Phase 1

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 14 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Single Center, Open-label, Drug Interaction Study of MGL-3196 With Atorvastatin in Healthy Subjects
Study Start Date : April 2016
Actual Primary Completion Date : May 2016
Actual Study Completion Date : May 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Drug Reactions

Arm Intervention/treatment
Treatment
Atorvastatin followed by MGL-3196 daily followed by separate co-administration of atorvastatin
Drug: Atorvastatin
Other Name: Lipitor

Drug: MGL-3196
Other Name: VIA-3196




Primary Outcome Measures :
  1. Area under the curve from the time of dosing extrapolated to infinity (AUC(0-inf)) of Atorvastatin as affected by MGL-3196 [ Time Frame: 72 hours ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Must be willing and able to provide written informed consent.
  • Healthy, non-smoking, male or female between the ages of 18 and 55 years (inclusive).
  • Body weight > 50 kg and BMI between 18 and 32 kg/m2 (inclusive).
  • If female, is of non-child bearing potential (i.e., surgically [bilateral oophorectomy, hysterectomy, hysteroscopic sterilization, or tubal ligation]. Or, is naturally sterile [>12 consecutive months without menses]) with verification by follicle stimulating hormone (FSH) at screening.
  • If male and non-vasectomized, must agree to use a condom with spermicide or abstain from sexual intercourse during the study until 30 days beyond the last dose of study drug. No restrictions are required for a vasectomized male provided his vasectomy has been performed 4 months or more prior to first dose of study drug. A male who has been vasectomized less than 4 months prior to study start must follow the same procedure as a non-vasectomized male.

Exclusion Criteria:

  • Any clinically significant abnormal findings during physical examination including blood pressure, heart rate or rhythm, clinical laboratory tests or 12-lead ECG.
  • Evidence or history of clinically significant hematological, endocrine, pulmonary, gastrointestinal, cardiovascular, renal, hepatic, neurological or psychiatric disease.
  • Thyroid stimulating hormone test at screening outside the normal range. Repeat testing is allowed once at the discretion of the Investigator.
  • Current or recent (<6 months) hepatobiliary disease; or aspartate aminotransferase (AST), alanine aminotransferase (ALT) or direct bilirubin greater than the upper limit of reference range at screening. Repeat testing is allowed once at the discretion of the Investigator.
  • Elevated creatine kinase (CK) at screening (one repeat test allowed).
  • Gilbert's syndrome.
  • Positive screening test for HIV antibody, Hepatitis B surface antigen or Hepatitis C antibody.
  • Abnormal screening ECG: including machine-read QTc >450 msec (confirmed by manual over read), QRS >110 msec, intermittent bundle branch block, frequent premature atrial or premature ventricular contractions, or any rhythm other than normal sinus rhythm which is interpreted by the Investigator to be clinically significant.
  • History of sensitivity to a similar study drug (e.g., Karo Bio KB2115 or Metabasis MB7811), or a history of important drug or other allergy (except for untreated, asymptomatic seasonal allergies at time of dosing) unless deemed not clinically significant by the Investigator.
  • History of sensitivity to thyroid medication.
  • History of intolerance to or adverse reaction to a statin, or history of myopathy including rhabdomyolysis.
  • Intolerance to beta-blockers (beta-blocker treatment could be appropriate to alleviate tachycardia if observed).
  • Participation in another clinical trial of an investigational drug (or medical device) within the last 30 days prior to the first dosing day, or who have been exposed to more than four new chemical entities within 12 months prior to the first dosing day.
  • Use of St. John's Wort within 28 days before the first dose of study drug.
  • Unwilling to forgo consumption of red wine, Seville oranges, grapefruit or grapefruit juice and/or pomelos, star fruit, grapefruit hybrids or other citrus juices from 5 days prior to the first dose of study drug and throughout the study.
  • Subjects with a history of drug or alcohol abuse as defined by the Diagnostic and Statistical Manual 5th Edition.
  • History of regular alcohol consumption exceeding 7 drinks/week for females or 14 drinks/week for men (1 drink = 5 ounces of wine or 12 ounces of beer or 1.5 ounces of hard liquor) within 6 months prior to screening.
  • Use of acetaminophen within 7 days before dosing and throughout the study except for the treatment of an adverse event as directed by the Investigator.
  • History of regular use of tobacco or nicotine containing products within the past 6 months relative to screening.
  • Positive urine drug screen or alcohol test at screening or Day -1.
  • Women who are pregnant or may become pregnant, or are nursing.
  • Strenuous physical activity which could cause muscle aches or injury, including contact sports, at any time from 3 days prior to first dose of study drug until completion of the study.
  • Excessive caffeine intake (>3 cups of coffee/day or equivalent).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02749578


Locations
United States, Arizona
Celerion
Tempe, Arizona, United States, 85283
Sponsors and Collaborators
Madrigal Pharmaceuticals, Inc.
Celerion
Investigators
Principal Investigator: Danielle Armas, MD Celerion

Responsible Party: Madrigal Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT02749578     History of Changes
Other Study ID Numbers: MGL-3196-04
First Posted: April 25, 2016    Key Record Dates
Last Update Posted: August 30, 2016
Last Verified: August 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Additional relevant MeSH terms:
Atorvastatin Calcium
Anticholesteremic Agents
Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors